# To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

> **NCT00946751** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 20 (actual)

## Conditions studied

- Seizure

## Interventions

- **DRUG:** Levetiracetam Tablets, 750 mg (Sandoz Inc.)
- **DRUG:** Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)

## Key facts

- **NCT ID:** NCT00946751
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946751, "To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00946751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*